CF101 (Piclidenoson) is a small molecule compound, it de-regulates signal transduction of the NF-κB by inducing A3AR activation which can resulting in apoptosis of inflammatory cells and attenuation of inflammatory responses.
In June 2022, Can-Fite Biopharma announced positive top-line results from the phase III study of CF101 in moderate to severe psoriasis overseas. The trial met its primary endpoint with statistically significant improvement and Cf101 had deman excellent safety profile.
There are more than 6.5 million people suffering from psoriasis in China with an incidence rate of 0.47%, where about 30% are with moderate-to-severe psoriasis. CF101 is expected to be a basic first-line treatment medicine for psoriasis.
